

Serum Homocysteine Levels in Patients with Non-Alcoholic Fatty Liver Disease

Dr.Nitin Bansal*, Dr. Nidhi Uniyal**

* Associate Professor, Department of Medicine, SGRRIM&HS, Patel Nagar, Dehradun

** Assistant Professor, Department of Medicine, SGRRIM&HS, Patel Nagar, Dehradun

Abstract- Aim: Non-alcoholic fatty liver disease (NAFLD) is a common disorder which causes serum liver enzyme elevation. Elevated homocysteine levels were demonstrated in fatty liver disease and chronic liver failure. However, enough data related with homocysteine levels in patients with NAFLD is not available. We aimed to find out whether there is an association between homocysteine levels and NAFLD.

Methods: fifty patients (35 men, 15 women) with NAFLD and 50 healthy adults (34 men, 16 women) enrolled in the study. Fasting blood samples were obtained and serum homocysteine levels were measured by fluorescence polarization immunoassay (FPIA) technology. Oral glucose tolerance test was performed and serum insulin, c-peptide, and lipoprotein levels were also measured.

Results: The mean serum homocysteine levels (+/-SD) were $13.44 \pm 3.10 \mu\text{mol/L}$ and $11.62 \pm 1.34 \mu\text{mol/L}$ in NAFLD and the control group, respectively. Mean serum homocysteine level in the NAFLD group was significantly higher than in control group ($p=0.015$). Fasting blood glucose, insulin, total cholesterol and low density lipoprotein (LDL) cholesterol were all found higher than the control group.

Conclusion: The serum homocysteine levels were significantly higher in patients with NAFLD than in control group. This may point out that high homocysteine levels may be associated with NAFLD

Index Terms- Homocysteine, non-alcoholic steatohepatitis, insulin resistance

hepatitis and chronically elevated plasma levels of alanine transaminase (ALT) in patients with negligible alcohol intake was first identified by Ludwig et al (1). The etiology of NAFLD is not known completely, but it is found in a variety of clinical settings, particularly in those patients with obesity, diabetes or hyperlipidemia (2-4). However, predisposing factor is not defined in some cases. In addition, the pathogenesis of NAFLD remains unclear. A central role for cytototoxic free fatty acids released from the accumulation of intrahepatic triglycerides is one mechanism in the pathogenesis of NAFLD. Related to this hypothesis, obesity which gives rise to insulin resistance, hypertriglyceridemia and leptin resistance are thought to play an important role (5). Eventough potentially, NAFLD can progress to fibrosis, cirrhosis, and eventually terminal liver failure (6).

Homocysteine is a product of methionine metabolism. Hyperhomocysteinemia has been found in patients with type 2 and type 1 diabetes mellitus associated with premature atherosclerosis (7,8). Several observations suggest that there might be links between insulin resistance and hyperhomocysteinemia (9-11). Higher levels of homocysteine were also demonstrated in healthy non-obese subjects (9). However, homocysteine is an atherogenic and thrombogenic risk factor (12) and may be involved hepatic fibrosis (13). Investigators reported in some studies that there was a link between homocysteine and alcoholic liver damage leading to fibrosis (14, 15).

The aim of this study is to evaluate possible association of homocysteine with NAFLD.

I. INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) which was characterized by the association of fatty liver and lobular

Table 1. The results of main biochemical tests and demographic findings in groups.

Group Variable	NAFLD (n=50)	Controls (n=50)	P
Sex (M/F)	35/15	34/16	Ns
Age, year (range)	42.15 ± 10.22 (29-60)	40.66 ± 7.95 (29-53)	Ns
BMI, kg/m^2 (range)	31.09 ± 4.33 (24.5-38)	31.38 ± 5.18 (22.4-39)	Ns
Waist circumference (cm)	96.84 ± 10.56	96.33 ± 10.07	Ns
Homocysteine ($\mu\text{mol/L}$)	13.44 ± 3.10	11.62 ± 1.34	0.015
Vitamin B ₁₂ (pg/mL)	282.84 ± 92.22	226.33 ± 33.45	Ns
Folate (ng/mL)	5.86 ± 1.43	4.94 ± 1.37	Ns
C-peptide (ng/mL)	1.82 ± 0.42	1.58 ± 0.29	Ns
Insulin (ng/mL)	12.36 ± 5.51	8.77 ± 2.37	0.009

ALT (U/L)	110.69 ± 19.58	50.66 ± 14.79	0.001
AST (U/L)	48.23 ± 13.10	24.77 ± 6.37	0.001
Glucose (ng/dL)	100.23 ± 8.96	87.66 ± 14.10	0.048
Total cholesterol (mg/dL)	200.76 ± 21.91	180.77 ± 14.52	0.041
Triglyceride (mg/dL)	154.61 ± 55.33	165.66 ± 87.87	Ns
LDL (mg/dL)	126.53 ± 19.86	105.68 ± 39.10	0.049
HDL (mg/dL)	43.30 ± 9.72	50.77 ± 18.45	Ns

II. MATERIAL AND METHODS

A total of 50 patients with NAFLD and age, sex and BMI matched 50 healthy subjects as control group were enrolled in the study. NAFLD patients had been referred for a comprehensive assessment of liver function because of the presence of ultrasonographic evidence of hepatic steatosis and elevated transaminases concentrations (alanine transaminases [ALT]) in excess of twice the upper normal limits at least one occasion during the preceding 6 months. For the diagnoses of NAFLD and to rule out other possible liver diseases, all patients with NAFLD underwent a detailed clinical and laboratory evaluation, including liver function tests, hepatitis markers and auto antibodies. Fatty liver was classified as grade 1 (mild), grade 2 (moderate) and grade 3 (severe). Alcohol consumption was absent in all subjects. Since all patients in NAFLD group were non smokers, smokers were excluded from the control group. Renal functions of the subjects were within normal limits. The patients with a history of drug usage in the last 2 months were excluded from the study.

Informed written consent was obtained for each subject. All blood samples were collected in the morning after an overnight fast. Blood samples were drawn in vacutainer blood-collecting tubes (Becton-Dickinson, Franklin Lakes, and NJ) according to standard hospital guidelines for venipuncture and sample collection. Homocysteine specimens were placed on ice and all specimens were transported to the laboratory within 30 minutes of collection. Serum was obtained after centrifugation at 2000 x g for 10 minutes, frozen, and stored at -20 °C until analysis. Serum total homocysteine concentrations were measured by using an IMX (Abbott diagn. USA) homocysteine assay. Assay is based on the fluorescence polarization immunoassay (FPIA) technology. Apart from that, serum insulin, c-peptide, serum lipoproteins and other biochemical tests were also evaluated in the NAFLD and control groups. All patients were asked to drink 75 gr glucose dissolved in 200 cc water and 2-hour glucose levels were detected. All results are expressed as mean ± SD. The mean homocysteine levels, vitamin B12, insulin, c-peptide and other serum parameters in both groups were compared by Mann-Whitney U test as the distribution between the groups were not normal. The same test was also used for the comparison of homocysteine levels. The correlations were given by the Pearson correlation coefficient (r). All analyses were two tailed and were conducted using computer-based statistics software (SPSS for Windows 9.0, 1998, SPSS, Chicago, IL). A p- value of less than 0.05 was accepted as statistically significant.

III. RESULTS

The results of main parameters studied in both groups are summarized in Table 1. In NAFLD Group, while there were 13 subjects who had impaired glucose tolerance, no subjects had diabetes. Control group had neither impaired glucose tolerance nor diabetes. As another risk factor when obesity is taken into consideration for NAFLD, in the study group all subjects except for 11 subjects had a BMI over 30. However, in the control group BMI less than 30 there were 10 subjects present. Serum homocysteine levels were significantly higher in patients with NAFLD (13.44±3.10 μmol/L) as compared with the control group (11.62 ± 1.34 μmol/L, p=0.015) (Figure 1). Serum vitamin B12 and folate levels were within normal limits and no statistical difference was present between two groups.

The evaluation of liver via ultrasonography for the fatty liver in NAFLD group demonstrated 14 subjects in grade 1; 22 subjects in grade 2; and 14 subjects in grade 3 hepatosteatosis. The insulin levels of the patients with NAFLD was significantly higher when compared with controls (p=0.009), but c-peptide levels did not differ in both groups. In addition, distribution of insulin levels was shown in Figure 2. The serum ALT, AST, glucose, total cholesterol and low density lipoprotein (LDL) cholesterol levels were statistically higher in NAFLD patients than in controls (p<0.05). Of the biochemical parameters, ALT, AST and glucose had positive correlation with serum homocysteine levels, respectively [(r= 0.52, p= 0.01), (r= 0.58, p= 0.004), (r= 0.51, p= 0.014)].

IV. DISCUSSION

Nonalcoholic fatty liver disease has been reported in patients with type 2 diabetes and obese persons for a long time (16,17). Studies indicate that this syndrome has a relationship with obesity, diabetes and hyperlipidemia (3,18,19), however there has been a small group with normal weight having normal fasting glucose and normal glucose tolerance without dyslipidemia (4). Nonalcoholic steatohepatitis (NAFLD) has a more limited area than hepatosteatosis itself. Recently, it was proposed that toxic affects of free fatty acids, insulin resistance syndromes and associated metabolic abnormalities are the current mechanisms that may be responsible (20). Apart from this, recent investigations showed that homocysteine levels were increased in hyperinsulinemic subjects with obesity and in the states of insulin resistance (10,11). Giltay et al. demonstrated that plasma homocysteine levels were increased even in non-obese subjects with insulin resistance (9). All of these data indicate that high levels of homocysteine may have relationship with insulin resistance. In our study, significantly high levels of serum

homocysteine were found in NAFLD patients. Serum glucose, insulin, total cholesterol, and LDL cholesterol were all found significantly higher than the the same age and BMI matched control group. These results support insulin resistance and metabolic abnormalities in patients with NAFLD. In some studies relationship between homocysteine levels, insulin resistance and metabolic syndrome could not be demonstrated and even contrary findings to our results were obtained (21, 22). These observations may be indicative of the results of high homocysteine levels rather than the cause of insulin resistance. It seems there are still unexplained points on homocysteine metabolism and metabolic syndrome.

Whether serum homocysteine elevation has a metabolic effect in the development of steatosis and steatohepatitis is not clear at present. One of the important results of the study is that higher serum homocysteine levels were detected in patients with NAFLD compared with controls.. However, this study is not enough to explain a possible relationship between homocysteine and hepatic fat accumulation and hepatic injury. In chronic alcoholism, alcoholic cirrhosis and experimental liver damages hyperhomocysteinemia and fatty liver were also shown (15,23,24). It is also shown that severe hyperhomocysteinemia due to cystathionine β -synthase deficiency should lead to widespread hepatosteosis and moreover to clinical manifestations like atherosclerosis, thrombosis, and osteoporosis (25,26). In one of their experimental studies Werstuck et al. found out that there has been a dysregulation in biosynthetic ways of cholesterol and triglyceride due to stress of homocysteine over endoplasmic reticulum and as a result of this, they concluded that progressive hepatosteosis and probably atherosclerotic lesions existed (27). Recent studies demonstrated that serum homocysteine levels are increased in patients with liver cirrhosis (14,28,29). Higher levels of hyperhomocysteinemia is more prominent in alcoholic cirrhosis meanwhile increase in homocysteine levels are also present in non-alcoholic cirrhosis (29,30). Garcia-Tevijano et al. showed that homocysteine levels were increased in patients with liver cirrhosis and they advocated that this increase was the marker for a decrease in hepatic functions and had a role in the development of hepatic fibrosis (14).

Apart from this, a very broad distribution of values in homocysteine levels of the healthy subjects has been described with the same technique (97.5th percentile at 16.6 $\mu\text{mol/L}$) (31). In our study laboratory reference range for homocysteine was 5-12 $\mu\text{mol/L}$. Values that we have obtained were in consistent with mild hyperhomocysteinemia. We think that these results may be because of small number of our cases.

In conclusion; the data suggest that serum homocysteine level is increased in NAFLD patients. The increase in homocysteine levels may be associated with metabolic abnormalities of NAFLD. Additionally, high homocysteine levels may be associated hepatic steatosis and steatohepatitis. However, further studies are needed to determine more clearly the role of homocysteine on hepatic steatosis and steatohepatitis.

REFERENCES

- [1] Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc* 1980; 55: 434-8
- [2] Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. *Hepatology* 1990;12:1106-10
- [3] Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. *Hepatology* 1990;11:74-80
- [4] Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. *Gastroenterology* 1994;107:1103-9
- [5] Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. *Am J Gastroenterol* 2002;97:14-24
- [6] Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. *Ann Intern Med* 1997;126:137-45
- [7] Hofmann MA, Kohl B, Zumbach MS, et al. Hyperhomocysteinemia and endothelial dysfunction in IDDM. *Diabetes Care* 1998;21:841-8
- [8] Hoogeveen EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. *Arterioscler Thromb Vasc Biol* 1998;18:133-8
- [9] Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD. Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects. *Atherosclerosis* 1998;139:197-8
- [10] Sanchez-Margalet V, Valle M, Ruz FJ, Gascon F, Mateo J, Goberna R. Elevated plasma total homocysteine levels in hyperinsulinemic obese subjects. *J Nutr Biochem* 2002;13:75-9
- [11] Meigs JB, Jacques PF, Selhub J, et al. Framingham Offspring Study. Fasting plasma homocysteine levels in the insulin resistance syndrome. *Diabetes Care* 2001;24:1403-10
- [12] Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. *Clin Chem* 1993;39:1764-79
- [13] Torres L, Garcia-Trevijano ER, Rodriguez JA, et al. Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes: a new role for homocysteine in liver fibrosis. *Biochim Biophys Acta* 1999;1455:12-22
- [14] Garcia-Tevijano ER, Berasain C, Rodriguez JA, et al. Hyperhomocysteinemia in liver cirrhosis: mechanism and role in vascular and hepatic fibrosis. *Hypertension* 2001; 38:1217-21
- [15] Halsted CH, Villanueva J, Chandler CJ, et al. Ethanol feedings of micropigs alters methionine metabolism and increases hepatocellular apoptosis and proliferation. *Hepatology* 1996;23:497-505
- [16] Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. *Am J Med* 1999;107:450-5
- [17] Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. *Diabetes* 2001;50:1844-5
- [18] Fong DG, Nehra V, Lindor KD, Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. *Hepatology* 2000;32:3-10
- [19] Kumar KS, Malet PF. Nonalcoholic steatohepatitis. *Mayo Clin Proc* 2000; 75:733-9
- [20] De Knecht RJ. Non-alcoholic steatohepatitis: clinical significance and pathogenesis. *Scand J Gastroenterol* 2001; (Suppl 234):88-92
- [21] Rosolova H, Simon J, Mayer O Jr, Racek J, Dierze T, Jacobsen DW. Unexpected inverse relationship between insulin resistance and serum homocysteine in healthy subjects. *Physiol Res* 2002;51: 93-8
- [22] Godsland IF, Rosankiewicz JR, Proudler AJ, Johnston DG. Plasma total homocysteine concentrations are unrelated to insulin sensitivity and components of the metabolic syndrome in healthy men. *J Clin Endocrinol Metab* 2001;86:719-23
- [23] Hultberg B, Berglund M, Andersson A, Frank A. Elevated plasma homocysteine in alcoholics. *Alcohol Clin Exp Res* 1993; 17: 687-689.
- [24] Lambert D, Benhayoun S, Adjalla C, et al. Alcoholic cirrhosis and cobalamin metabolism. *Digestion* 1997; 58:64-71

- [25] Mudd SH, Levy HL, Skovby F. Disorders of transsulfation. In: Scriver CR, Beaudet AL, Sly WS, and Valle D, Eds. The metabolic basis for inherited diseases. New York : McGraw-Hill, 1989; 693–734
- [26] Gaull G, Sturman JA, Schaffner F. Homocystinuria due to cystathionine synthase deficiency: enzymatic and ultrastructural studies. *J Pediatr* 1974; 84:381–90
- [27] Werstuck GH, Lentz SR, Dayal S, et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. *J Clin Invest* 2001; 107:1263–73
- [28] Bosty-Westphal A, Petersen S, Hinrichsen H, Czech N, J Muller M. Increased plasma homocysteine in liver cirrhosis. *Hepatology* 2001; 20:28-38
- [29] Bosty-Westphal A, Ruschmeyer M, Czech N, et al. Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation. *Am J Clin Nutr* 2003;77:1269-77
- [30] Look MP, Riezler R, Reichel C, et al. Is the increase in serum cystathionine levels in patients with liver cirrhosis a consequence of impaired homocysteine transsulfuration at level of gamma-cystathionase? *Scand J Gastroenterol* 2000; 35:866–72
- [31] Cotton F, Wautrecht JC, Lechevin V, et al. Reference intervals for plasma homocysteine by the AxSYM immunoassay after collection in fluoride tubes. *Clin Chem* 2003; 49:315-7

AUTHORS

First Author – Dr. Nitin Bansal, Associate Professor,
Department of Medicine, SGRRIM&HS, Patel Nagar, Dehradun,
nitinbansal18@hotmail.com

Second Author – Dr. Nidhi Uniyal, Assistant Professor,
Department of Medicine, SGRRIM&HS, Patel Nagar, Dehradun

Third Author –Dr. Priyanka V Kashyap, Assistant Professor

Fourth Author –Dr. Amit Varma, Professor & Head,
Department of Medicine